LFG
AGMB

Larson Financial Group’s AgomAb Therapeutics NV AGMB Stock Holding History

Larson Financial Group’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.06K Buy
+698
New +$7.86K ﹤0.01% 2466

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Larson Financial Group's AGMB Position: Q2 2026 in Review

Larson Financial Group opened a new position in AgomAb Therapeutics NV (AGMB) in Q2 2026: 698 shares worth $9.06K. The stake represents ﹤0.01% of the portfolio and ranks #2466 among its holdings.

34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Larson Financial Group held 698 shares of AgomAb Therapeutics NV worth $9.06K as of Q2 2026.
  • AgomAb Therapeutics NV was a new Larson Financial Group position in Q2 2026.
  • AgomAb Therapeutics NV made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2466 holding.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.